homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

June 1, 2023

Seagen

In Bothell, biotechnology company Seagen announced that its stockholders have approved Pfizer's acquisition of the company for $229 per share in cash. More than 99% of the shares voted at a special meeting were in favor of the deal. Pending regulatory approvals, the acquisition is expected to close late this year or in early 2024. Seagen develops cancer medicines.




Email or user name:
Password:
 
Forgot password? Click here.